Results 1 to 10 of about 21,136 (195)
Microorganisms, 2022 Streptokinase is an enzyme that can break down the blood clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism.
Armi M. Chaudhari +5 more
doaj +1 more source
PLASMINOGEN ACTIVATION BY LOW MOLECULAR WEIGHT STREPTOKINASE AND FIBRIN EFFECT [PDF]
Biotechnologia Acta, 2014 The purpose is to study the plasminogen-activating activity of 36 kDa-streptokinase fragment, influences of desAB-fibrin on this process and low molecular weight streptokinase on plasmin catalytic properties as well. The 36 kDa-fragment lacking the 63
E. I. Yusova
doaj +1 more source
Acta Medica Iranica, 2022 Early administration of thrombolytic agents is standard for patients presenting with acute myocardial infarction (MI). Also, prolonged QT intervals indicate a higher risk for sudden death in patients with MI.
Reza Ghasemi +3 more
doaj +1 more source
Acta Medica Iranica, 2022 Early administration of thrombolytic agents is the standard treatment and crucial for the outcome for patients presenting with acute myocardial infarction (MI). This study was conducted to evaluate the door to needle time of streptokinase administration
Reza Ghasemi +3 more
doaj +1 more source
Egyptian Journal of Chest Disease and Tuberculosis, 2023 Context Parapneumonic effusion and empyema are commonly encountered by the pulmonologist. The decision regarding management is still challenging.
Mervat A Abou Ismail +3 more
doaj +1 more source
Contribution of Streptokinase-Domains from Groups G and A (SK2a) Streptococci in Amidolytic /Proteolytic Activities and Fibrin-Dependent Plasminogen Activation: A Domain-Exchange Study [PDF]
Iranian Biomedical Journal, 2020 Background: SK, a heterogeneous PA protein from groups A, C, and G streptococci (GAS, GCS, GGS, respectively) contains three structural domains (SKα, SKβ, and SK).
Maryam Rafipour +4 more
doaj +1 more source
The International Journal of Frontier Sciences, 2017 Background: To compare between the outcomes of streptokinase and primary PCI in acute myocardial infarction. The inappropriate treatment, misdiagnosis, contraindications of procedures can result in complications of procedures and increased mortality of ...
Zarnab Tariq, Majid Kaleem
doaj +1 more source
Evaluation of clinical efficacy of streptokinase by comparison with the thrombolytic agent on animal model [PDF]
Brazilian Journal of BiologyCardiovascular disorders, including acute myocardial infarction (AMI), often lead to blood clot formation, impacting blood circulation. Streptokinase, a cost-effective and widely available thrombolytic agent, is crucial in treating thrombosis. This study
S. Yousaf +6 more
doaj +1 more source
Cloning and expression of truncated and intact streptokinase molecules in E.coli and evaluation of their biological activities [PDF]
مجله بیوتکنولوژی کشاورزی, 2010 Streptokinase is the most utilized drug for thrombolytic therapy. However, due to its nonhuman origin and nonspecific activity in the absence of fibrin, its application may encounter side effects such as allergic reactions and hemorrhage respectively. It
Reza Arabi +7 more
doaj +1 more source
Jurnal Teknologi Laboratorium, 2019 Streptokinase is a extracellular enzyme which is extracted from strains of beta Hemolytic streptococcus. The enzyme is a non-protease plasminogen activator that activates plasminogen to plasmin and degrades fibrin clot through its specific lysine binding
Pavan Kumar Vadla +2 more
doaj +1 more source